Keyword Analysis & Research: recarbrio
Keyword Research: People who searched recarbrio also searched
Search Results related to recarbrio on Search Engine
-
Dosing and Administration for RECARBRIO™ (imipenem, …
https://www.merckconnect.com/recarbrio/dosing-administration/
WEBIndications and Usage. RECARBRIO is indicated for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae ...
DA: 76 PA: 59 MOZ Rank: 69
-
FDA approves new treatment for complicated urinary tract and
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-complicated-urinary-tract-and-complicated-intra-abdominal-infections
WEBJuly 17, 2019. The U.S. Food and Drug Administration has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract...
DA: 31 PA: 66 MOZ Rank: 64
-
FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial …
https://www.fda.gov/news-events/press-announcements/fda-approves-antibiotic-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated
WEBJun 5, 2020 · 240-731-9982. Consumer: 888-INFO-FDA. The FDA has approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and...
DA: 29 PA: 56 MOZ Rank: 88
-
Drug Trial Snapshot: RECARBRIO | FDA
https://www.fda.gov/drugs/resources-information-approved-drugs/drug-trial-snapshot-recarbrio
WEBRECARBRIO is a drug administered by a health care professional directly into the bloodstream through a needle in the vein. This is known as an intravenous, or IV, infusion. It takes about 30...
DA: 32 PA: 46 MOZ Rank: 13
-
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and …
https://www.merck.com/news/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habp-vabp/
WEBSave. June 5, 2020 6:50 am ET. RECARBRIO is Indicated to Treat Multiple Infections Caused by Susceptible Gram-Negative Bacteria in Adults. KENILWORTH, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New ...
DA: 59 PA: 93 MOZ Rank: 59
-
HIGHLIGHTS OF PRESCRIBING INFORMATION RECARBRIO …
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212819s002lbl.pdf
WEBRECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta lactamase inhibitor, indicated in patients 18 years of age...
DA: 41 PA: 69 MOZ Rank: 35
-
Frequently asked questions for RECARBRIO™ (imipenem, …
https://www.merckconnect.com/recarbrio/frequently-asked-questions/
WEBRECARBRIO is indicated for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae, Escherichia coli, Haemophilus i...
DA: 31 PA: 90 MOZ Rank: 53
-
Recarbrio | European Medicines Agency
https://www.ema.europa.eu/en/medicines/human/EPAR/recarbrio
WEBOverview. Recarbrio is an antibiotic for treating adults with the following infections: lung infections caught in hospital (hospital-acquired pneumonia), including ventilator-associated pneumonia (pneumonia caught while on a ventilator, which is a machine that helps a patient to breathe); infection that has spread into the blood (bacteraemia ...
DA: 92 PA: 31 MOZ Rank: 18
-
FDA Approves Merck’s RECARBRIO™ (imipenem ... - Merck | Home
https://www.merck.com/news/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-complicated-urinary-tract-and-complicated-intra-abdominal-bacterial-infections-w/
WEBJul 17, 2019 · RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella p...
DA: 50 PA: 88 MOZ Rank: 80
-
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
https://www.ema.europa.eu/en/documents/product-information/recarbrio-epar-product-information_en.pdf
WEBRecarbrio is indicated for: Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults (see sections 4.4 and 5.1). Treatment of bacteraemia that occurs in association with, or is suspected …
DA: 3 PA: 26 MOZ Rank: 20